Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus
January 07, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
March 04, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...
Hemispherx Biopharma Gains Regulatory Approval in Latin America
January 26, 2012 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that ANMAT (Administracion Nacional de Medicamentos,...
Hemispherx Biopharma to Present at Noble Financial Capital Markets' Annual Equity Conference
May 16, 2011 12:21 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 16, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that its Senior Advisor to the CEO, Wayne Pambianchi, will...